| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Notes: |
| Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand. |
|
| Chapter Links... |
 Haematology and Oncology Protocols and Guidelines |
| DSU: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? (March 2019) |
| Details... |
| 08.01 |
Cytotoxic drugs |
|
|
| 08.01 |
Side-effects of cytotoxic drugs |
|
|
| 08.01 |
Drugs for cytotoxic-induced side-effects |
|
|
Calcium Folinate
|
 Restricted
|
Calcium Folinate Tablets
Calcium Folinate Injection
Calcium Folinate Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Disodium Folinate
|
Restricted
|
Disodium Folinate Injection
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Mesna
|
Restricted
|
Mesna Injection
Mesna Tablets
Mesna Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.01 |
Alkylating drugs |
|
|
Bendamustine
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
Bendamustine is also available for other indications funded by the CDF
|
Cancer Drug Fund - Bendamustine
NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (February 2011)
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017)
|
Chlorambucil
|
Restricted
|
Chlorambucil Tablets
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Cyclophosphamide
(Chemotherapy)
|
Restricted
|
Cyclophosphamide Suspension
Cyclophosphamide injection
Cyclophosphamide Tablets
Cyclophosphamide Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Melphalan
|
Restricted
|
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.02 |
Anthracyclines and other cytotoxic antibiotics |
|
|
Bleomycin
|
Restricted
|
Bleomycin Injection
Bleomycin Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Doxorubicin Hydrochloride
|
Restricted
|
- Doxorubicin Injection
- Liposomal doxorubicin Injection
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016)
|
Epirubicin hydrochloride
|
Restricted
|
Epirubicin Injection
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Mitomycin
|
Restricted
|
Mitomycin Injection
Mitomycin C Injection
Mitomycin C bladder instillation
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Pixantrone intravenous infusion (Pixuvri )
|
Restricted
|
Pixantrone Intravenous Infusion
Restricted for use as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas in-line with NICE TA306.
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma (February 2014)
|
| 08.01.03 |
Antimetabolites |
|
|
Azacitidine (Vidaza)
|
Restricted
|
Supported for use in line with NICE TA218.
|
NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (March 2011)
|
Capecitabine
|
Restricted
|
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes C) colon cancer (April 2006)
NICE TA191: Capecitabine for the treatment of advanced gastric cancer (July 2010)
|
Cladribine
|
Restricted
|
- Cladribine Injection (LITAK® for subcutaneous injection)
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
MHRA Drug Safety Update: Cladribine (Litak, Leustat) for leukaemia: reports of progressive multifocal encephalopathy (PML); stop treatment if PML suspected (December 2017)
|
Cytarabine
|
Restricted
|
Cytarabine Injection
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Fludarabine Phosphate
|
Restricted
|
- Fludarabine Tablets
Supported for use in line with NICE TA116 and TA29.
|
NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (February 2007)
NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (September 2001)
|
Fluorouracil
(Chemotherapy)
|
Restricted
|
Fluorouracil Injection
Fluorouracil Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Gemcitabine
|
Restricted
|
|
NICE TA116: Gemcitabine for the treatment of metastatic breast cancer (January 2007)
NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer (May 2001)
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017)
|
Mercaptopurine
|
Restricted
|
Mercaptopurine Tablets
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
Mercaptopurine and Azathioprine Shared Care Guideline for Inflammatory Bowel Disease
|
Methotrexate
(Chemotherapy)
|
Restricted
|
Methotrexate Injection
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
DSU: Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (September 2020)
EMA: EMA reviewing risk of dosing errors with methotrexate (April 2018)
SPS Q&A: Should patients drink alcohol whilst taking long-term low-dose methotrexate? (December 2018)
|
Pemetrexed
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008)
NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer (September 2009)
NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer (August 2017)
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (August 2016)
|
Trifluridine-tipiricil (Lonsurf)
|
Restricted
|
- Trifluridine Tipiricil Tablets (Lonsurf®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA405: Trifluridinetipiracil for previously treated metastatic colorectal cancer (August 2016)
|
| 08.01.04 |
Vinca alkaloids and etoposide |
|
|
Etoposide
|
Restricted
|
Etoposide Capsules
Etoposide Injection
Etoposide Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Vinblastine Sulphate
|
Restricted
|
Vinblastine Injection
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Vincristine Sulphate
|
Restricted
|
Vincristine Injection
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Vinorelbine
|
Restricted
|
- Vinorelbine Injection (reserved for patients unable to swallow capsules)
- Vinorelbine Capsules
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.05 |
Other antineoplastic drugs |
|
|
Atezolizumab infusion
|
Restricted
|
Consultant Oncologist use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (December 2017)
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (May 2018)
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (June 2018)
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019)
NICE TA638:Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (July 2020)
NICE TA639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (July 2020)
|
Axitinib (Inlyta)
|
Restricted
|
Patients who require treatment of renal cell carcinoma should be referred to Leeds Teaching Hospital Trust
Axitinib is not stocked at Airedale NHS Foundation Trust
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (Februaury 2015)
|
Brentuximab infusion (Adcetris)
|
Restricted
|
For treatment of CD30-positive cutaneous T-cell lymphoma in-line after at least one other therapy (second-line) with NICE TA577.
Consultant Haematologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2017)
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (October 2017)
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2018)
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (April 2019)
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (August 2020)
|
Crizotinib (Xalkori)
|
Restricted
|
- Crizotinib Capsules (Xalkori®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
MHRA Drug Safety Update: Crizotinib - risk of cardiac failure (November 2015)
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (September 2016)
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (December 2016)
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (July 2018)
|
Daratumumab infusion ( Darzalex)
|
Restricted
|
- Daratumumab infusion (Darzalex®)
Consultant Haematologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
DSU: Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus (August 2019)
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (March 2018)
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (April 2019)
|
Dasatinib (Sprycel)
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
|
Durvalumab
|
Restricted
|
Supported for treatment of locally advanced non small-cell lung cancer after platinum-based chemo radiation in-line with NICE TA578.
Consultant oncologist use only.
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (May 2019)
|
Eribulin ( Halaven)
|
Restricted
|
- Eribulin Solution for Injection
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (December 2016)
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (March 2018)
|
Ibrutinib (Imbruvica)
|
Restricted
|
Consultant Haematologist use only
Ibrutinib is only available via the CDF. For further information see the link below.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drugs Fund
Drug Safety Update:Ibrutinib: reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections (August 2017)
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (January 2017)
NICE TA491: Ibrutinib for treating Waldenstroms macroglobulinaemia (November 2017)
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma (January 2018)
|
Isatuximab infusion (Sarclisa)
|
Restricted
|
For the treatment of relapsed and refractory myeloma (with pomalidomide and dexamethasone) under MHRA Early Access to medicines Scheme.
Consultant Haematologist use only.
|
|
|
Neratinib (Nerlynx)
|
Restricted
|
- Niraparib tablets (Nerlynx®)
Approved as an option for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab in-line with provisional NICE recommendations.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
|
|
Niraparib (Zejula)
|
Restricted
|
- Niraparib Capsules (Zejula®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
Consultant Oncologist use only
|
TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (July 2018)
|
Nivolumab (Opdivo)
|
Restricted
|
Consultant Oncologist use only.
For use at Specialist Centres only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
DSU: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (October 2019)
MHRA Drug Safety Update: Nivolumab, pembrolizumab: reports of organ transplant rejection (July 2017)
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (July 2017)
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (November 2017)
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (November 2017)
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (November 2017)
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (June 2018)
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (January 2019)
TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (May 2019)
|
Olaparib (Lynparza)
|
Formulary
|
- Olaparib capsules - For the treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer in-line with NICE TA381.
- Olaparib tablets - For maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in-line with NICE TA598.
Consultant Medical Oncologist use only
|
 DSU: Olaparib: Risk of medication errors with new pharmaceutical form (May 2018)
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016)
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (August 2019)
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (January 2020)
SSC2101 - Olaparib 2nd and 3rd line treatment of ovarian, fallopian tube or peritoneal cancer (December 2019)
|
Pembrolizumab (Keytruda)
|
Restricted
|
For use at specialist centres only in line with NICE TA357 and TA366.
For treating for treating PD-L1-positive non-small-cell lung cancer after chemotherapy in-line with NICE TA428 and NICE TA447.
For locally advanced or metastatic urothelial cancer after platinum-containing therapy in-line with NICE TA519
Consultant Medical Oncologist use only
Approved for Hodgkin lymphoma in-line with NICE TA540
Consultant haematologist use only
Approved for first-line treatment (in combination with pemetrexed and cisplatin chemotherapy) of metastatic, non-squamous non-small-cell lung cancer in patients with no EGFR or ALK-positive mutations with NICE TA557.
Consultant Oncologist use only
Approved for use (in combination with carboplatin and paclitaxel) as an option for untreated metastatic squamous NSCLC in-line with NICE TA600
Consultant Medical Oncologist use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Drug Safety Update: Nivolumab, pembrolizumab: reports of organ transplant rejection (July 2017)
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (September 2017)
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum chemotherapy (April 2018)
NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (June 2018)
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (July 2018)
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (September 2018)
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (December 2018) [For Specialist or Tertiary Centre use only]
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (January 2019)
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (September 2019)
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (September 2020)
NICE TA366: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
|
Pertuzumab (Perjeta)
|
Restricted
|
Pertuzumab is also available for some indications via the CDF. For further information see the link below.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drug Fund
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (December 2016)
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (March 2019)
|
Ponatinib (Iclusig)
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Drug Safety Update: Ponatinib (Iclusig): risk of vascular occlusive eventsupdated advice on possible dose reduction (April 2017)
DSU: Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome (October 2018)
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (June 2017)
|
Ribociclib (Kisqali)
|
Restricted
|
- Ribociclib tablets (Kisqali®)
Approved by D&TC as a treatment option (with fulvestrant) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in-line with NICE TA593
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
|
|
Rucaparib tablets (Rubraca)
|
Restricted
|
Consultant Oncologist use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (November 2019)
|
Venetoclax
|
Restricted
|
- Venetoclax film-coated tablets
Consultant Haemotologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (November 2017)
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (February 2019)
|
|
|
| 08.01.05 |
Amsacrine |
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
| 08.01.05 |
Bevacizumab |
|
|
Bevacizumab (Avastin)
(Oncology)
|
Restricted
|
Bevacizumab is only available for via the CDF. For further information see the link below.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drug Fund: Bevacizumab
MHRA Drug Safety Update:Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)
NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) [Do not recommend]
NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) [Do not recommend]
|
| 08.01.05 |
Bexarotene |
|
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib (Velcade)
|
Restricted
|
Bortezomib is also available for some indications via the CDF list. See link below for further information.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drugs Fund
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma (October 2007)
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011)
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma (December 2015)
|
Carfilzomib (Kyprolis)
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
DSU: Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events (August 2019)
DSU: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus (November 2019)
NICE TA457: Carfilzomib for previously treated multiple myeloma (July 2017)
|
Ixazomib (Ninralo)
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab (Erbitux)
|
Restricted
|
Available via NHSE. See the link below for further information.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA118: Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer (Updated January 2012). NOT RECOMMENDED
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) [Specialist Centre Only)
NICE TA172: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (June 2009) NOT RECOMMENDED
NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (August 2017)
TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
|
| 08.01.05 |
Crisantaspase |
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine
|
Restricted
|
Dacarbazine Injection
Dacarbazine Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide
|
Restricted
|
Hydroxycarbamide Capsules
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.05 |
Ipilimumab |
|
|
| 08.01.05 |
Mitotane |
|
|
| 08.01.05 |
Panitumumab |
|
|
Panitumumab infusion (Vectibix)
|
Restricted
|
- Panitumumab infusion (Vectibix®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
|
| 08.01.05 |
Pentostatin |
|
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin
|
Restricted
|
Carboplatin Injection
Carboplatin Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Cisplatin
|
Restricted
|
Cisplatin Infusion
Cisplatin Injection
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Oxaliplatin
|
Restricted
|
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes C) colon cancer (April 2006)
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)
|
| 08.01.05 |
Porfimer sodium and temoporfin |
|
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine
|
Restricted
|
Procarbazine Capsules
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Abemaciclib tablets (Verzenios )
|
Restricted
|
- Abemaciclib tablets (Verzenios®)
Consultant Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (February 2019)
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
|
Afatinib (Giotrif)
|
Restricted
|
- Afatinib Tablets (Giotrif®)
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (April 2014)
|
Alectinib capsules (Alecensa)
|
Restricted
|
- Alectinib Capsules (Alecensa®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (August 2018)
|
Bosutinib (Bosulif)
|
Restricted
|
- Bosutinib Tablets
Consultant Haematologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation(May 2016)
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia (August 2016)
|
Brigatinib tablets (Alunbrig)
|
Restricted
|
- Brigatinib tablets (Alunbrig®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA571:Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (March 2019)
|
Ceritinib capsules (Zykadia)
|
Restricted
|
- Ceritinib Capsules (Zykadia®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (June 2016)
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer (January 2018)
|
Dacomitinib (Vizimpro)
|
Restricted
|
Consultant Oncology use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (August 2019)
|
Erlotinib
|
Restricted
|
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer [Not recommended] (June 2011)
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
|
Everolimus (Afinitor)
|
Restricted
|
- Everolimus Tablets (Afinitor®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (June 2017) [Specialist Centre Only]
NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011) NOT RECOMMENDED [Specialist Centre Only]
NICE TA348: Everolimus for preventing organ rejection in liver transplantation (July 2015)
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment (Feb 2017) [Specialist Centre Only]
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (January 2018) [Specialist Centre Only]
|
Gefitinib
|
Restricted
|
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010)
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
|
Idelalisib (Zydelig)
|
Restricted
|
|
EMA recommends new safety measures for Zydelig (March 2016)
MHRA Drug Safety Update: Idelalisib (Zydelig): updated indications and advice on minimising the risk of infection (September 2016)
NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia (October 2015)
NICE TA604: Idelalisib for treating refractory follicular lymphoma (October 2019)
|
Imatinib
|
Restricted
|
|
MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (November 2010)
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia (January 2016)
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)
|
Larotrectinib 20mg/mL oral solution (Vitrakvi)
|
Restricted
|
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours (May 2020)
|
Lorlatinib (Lorviqua)
|
Restricted
|
- Lorlatinib Tablets (Lorviqua®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (May 2020)
|
Nilotinib (Tasigna)
|
Restricted
|
- Nilotinib Tablets
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
NICE TA241: Dasatinib, high-dose imatinib and nilotinib for use in patients who are resistant or intolerant to imatinib (January 2012)
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
|
Nintedanib capsules (Vargatef)
|
Restricted
|
- Nintedanib Capsules (Vargatef®)
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (July 2015)
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis (January 2016)
|
Osimertinib mesylate ( Tagrisso)
|
Restricted
|
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (October 2016)
|
Palbociclib (Ibrance)
|
Restricted
|
- Palbociclib capsules
- Palbociclib capsules with fulvestrant injection
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (January 2020)
|
Ribociclib (Kiskali)
|
Restricted
|
- Ribociclib Tablets
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (August 2019)
|
Ruxolitinib (Jakavi)
|
Restricted
|
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (March 2016)
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel (Jevtana)
|
Restricted
|
- Cabazitaxel Concentrate for Infusion
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (May 2016)
|
Docetaxel
|
Restricted
|
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006)
NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
|
Paclitaxel
|
Restricted
|
- Paclitaxel Injection
- Paclitaxel Infusion
- Paclitaxel as albumin-bound nanoparticles Infusion
|
NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (October 2015)
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017)
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer (January 2003)
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan Hydrochloride
|
Restricted
|
|
DSU: Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events (March 2019)
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014)
NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (April 2017)
|
Topotecan
|
Restricted
|
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009)
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016)
NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)
|
| 08.01.05 |
Trabectedin |
|
|
| 08.01.05 |
Trastuzumab |
|
|
Trastuzumab (Herceptin Ontruzant)
|
Restricted
|
- Trastuzumab Intravenous Injection (Herceptin®)
- Trastuzumab Subcutaneous Injection (Herceptin ®)
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010)
NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012)
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002)
|
Trastuzumab emtansine (Kadcyla)
|
Restricted
|
- Trastuzumab emtansine Powder for Concentrate for Solution for Infusion (Kadcyla®)
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (July 2017)
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (June 2020)
|
| 08.01.05 |
Tretinoin |
|
|
| 08.02 |
Drugs affecting the immune response |
|
|
| 08.02 |
Immunosuppressant therapy |
|
|
| 08.02.01 |
Antiproliferative immunosuppressants |
|
|
Azathioprine
|
Formulary
|
 Azathioprine Tablets
Azathioprine injection
|
 Azathioprine and Mercaptopurine Gastroenterology Shared Care Guideline
Azathioprine Rheumatology Shared Care Guideline
Link to Leeds Share Care Guideline: Adult liver transplant
Link to Leeds Shared Care Guideline: Adult renal transplant
|
Mycophenolate Mofetil
|
Restricted
|
- Mycophenolate Mofetil Capsules
- Mycophenolate mofetil 1gram/5ml suspension
Prophylaxis of acute renal, cardiac or hepatic transplant rejection (in combination with ciclsporin and corticosteroids) under specialist supervision
Also supported for use by consultants for the following specialties (unlicensed uses):
1. Rheumatology - Usually considered in active SLE or other serious connective tissue diseases and vasculitides
2. Gastroenterology – considered in very occasional inflammatory bowel disease patients and autoimmune hepatitis
3. Neurology – usually considered in myasthenia gravis as steroid sparing agent.
4. Respiratory
a. idiopathic pulmonary fibrosis intolerant to azathioprine often awaiting lung transplant
b. pulmonary vasculitides (Wegner’s granulomatosis, CSS and microscopic polyangitis)
|
DSU: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018)
MHRA Drug Safety Update: Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis (January 2015)
MHRA Drug Safety Update: Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men (December 2015)
Mycophenolate mofetil Shared Care Guideline
NICE TA85 - Immunosuppressive therapy for renal transplantation in adults (September 2004)
|
| 08.02.02 |
Corticosteroids and other immunosuppressants |
|
|
Ciclosporin
|
Formulary
|
Ciclosporin Capsules
Ciclosporin Oral Solution
|
Ciclosporin Rheumatology Shared Care Guideline
|
Tacrolimus (Adoport, Advagraf, Prograf)
|
Formulary
|
For existing patients only. Prescribe by brand name.
|
Link to Leeds Amber Drug Guidance: Tacrolimus for renal or liver transplant
|
|
|
|
|
| 08.02.03 |
Rituximab and alemtuzumab |
|
|
Obinutuzumab (Gazyvaro)
|
Restricted
|
- Obinutuzumab Infusion (Gazyvaro®)
Consultant Haematologist use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015)
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017)
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma (March 2018)
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (May 2020)
|
Ofatumumab (Arzerra)
|
Restricted
|
- Ofatumumab Infusion (Arzerra®)
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015)
|
Rituximab (MabThera Truxima)
|
Formulary
|
- Rituximab Infusion
- Rituximab Subcutaneous Injection
|
NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkins lymphoma (February 2008)
NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)
NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)
NICE TA65 Rituximab for agressive non-Hodgkins lymphoma (September 2003)
TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014)
|
| 08.02.04 |
Other immunomodulating drugs |
|
|
Dimethyl fumarate (Tecfidera)
|
Restricted
|
- Dimethyl fumarate Capsules
Available in line with NICE TA320 at the following specialist centres:
Leeds Teaching Hospital Trust, Sheffield Teaching Hospital, Hull and East Yorkshire, York and Mid Yorks Trusts.
|
MHRA Drug Safety Update: Dimethyl fumarate: fatal PML in an MS patient with severe, prolonged lymphopenia (March 2015)
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (August 2014)
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis (September 2017)
|
Lenalidomide ( Revlimid)
|
Restricted
|
Use restricted to Consultant Haematologists only.
Lenalidomide is also available for other indications via the Cancer Drugs Fund.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drugs Fund - Lenalidomide
Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
Drug Safety Update: Lenalidomide (Revlimid): New important advice regarding viral reactivation (November 2016)
MHRA Drug Safety Update: Risk of thrombosis and thromboembolism (Feb 2011)
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy (June 2009)
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (September 2014)
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (June 2019)
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma (June 2019)
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma (April 2020)
|
Panobinostat (Farydak)
|
Formulary
|
Consultant haematologist only.
|
NICE TA380: Panobinostat for treating multiple myeloma after at least two previous treatments (January 2016)
|
Pomalidomide (Imnovid)
|
Restricted
|
Haematology use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
MHRA Drug Safety Update: Pomalidomide (Imnovid): risk of hepatitis B reactivation (April 2016)
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (January 2017)
|
Thalidomide
|
Restricted
|
Consultant Haematologist use only
|
Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
Drug Safety Update: Thalidomide - reduced starting dose in patients older than age 75 years (December 2015)
MHRA Drug Safety Update: Thalidomide: Risk of second primary malignancies (May 2013)
MHRA Drug Safety Update: Thalidomide: risk of arterial and venous thromboembolism (July 2011)
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (July 2011)
|
|
|
| 08.02.04 |
Interferon Alfa |
|
|
Interferon Alfa
|
Restricted
|
Interferon Alfa-2A Injection
Reserved for Consultant Haematologist use
|
|
|
Peginterferon Alfa
|
Restricted
|
Peginterferon Alfa-2B Prefilled Pen
Consultant Gastroenterologist use only for the treatment of hepatitis C in combination with ribavirin capsules in line with NICE TA106, TA200 and TA75.
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (August 2006)
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (September 2010)
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (November 2013)
|
| 08.02.04 |
Interferon beta |
|
|
| 08.02.04 |
Aldesleukin |
|
|
| 08.02.04 |
Glatiramer acetate |
|
|
 |
Available via specialist centres only. |
|
| 08.02.04 |
Natalizumab |
|
|
| 08.03 |
Sex hormones and hormone antagonists in malignant disease |
|
|
| 08.03.01 |
Oestrogens |
|
|
Diethylstilbestrol (Stilboestrol)
|
Restricted
|
Diethylstilbestrol Tablets
For the treatment of prostate cancer under the recommendation of Consultant Oncologist.
|
|
|
Ethinylestradiol
(Ethinyloestradiol)
|
Restricted
|
Ethinylestradiol Tablets
For the treatment of prostate cancer under the recommendation of Consultant Oncologist.
|
|
|
| 08.03.02 |
Progestogens |
|
|
Medroxyprogesterone Acetate
|
Formulary
|
Medroxyprogesterone Acetate Tablets
Medroxyprogesterone Acetate Injection
|
|
|
Megestrol Acetate
|
Formulary
|
Megesterol Acetate Tablets
|
|
|
| 08.03.03 |
Androgens |
|
|
| 08.03.04 |
Hormone antagonists |
|
|
| 08.03.04.01 |
Breast cancer |
|
|
|
Anastrozole (Arimidex )
|
Formulary
|
Anastrazole Tablets
|
NICE CG164: Familial Breast Cancer (updated March 2017)
|
Exemestane (Aromasin)
|
Formulary
|
Exemestane Tablets
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
|
Fulvestrant
|
Restricted
|
Fulvestrant Injection
Not recommended for use.
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (December 2011)
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (January 2018)
|
Letrozole
|
Formulary
|
Letrozole Tablets
|
|
|
Tamoxifen
|
Formulary
|
Tamoxifen Tablets
Tamoxifen SF Solution
|
NICE CG164: Familial Breast Cancer (updated March 2017)
|
|
|
|
|
|
|
| 08.03.04.02 |
Prostate cancer and gonadorelin analogues |
|
|
Degarelix Injection
|
Restricted
|
- Degarelix Subcutaneous Injection
Treatment is to be initiated by a Consultant Urologist and the loading dose (120mg) provided by the Trust. Subsequent maintenances doses (80mg) are to be provided by the patient’s GP.
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer (August 2016)
|
|
|
| 08.03.04.02 |
Gonadorelin analogues |
|
|
| 08.03.04.02 |
Anti-androgens |
|
|
Abiraterone Acetate
|
Restricted
|
- Abiraterone Acetate Tablets
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
EMA: Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone (March 2018)
NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (July 2016)
NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (July 2016)
|
Bicalutamide
|
Restricted
|
Bicalutamide Tablets
|
|
|
Cyproterone Acetate
|
Restricted
|
Cyproterone Tablets
|
Drug Safety Update: Cyproterone acetate: new advice to minimise risk of meningioma (June 2020)
|
Enzalutamide (Xtandi )
|
Restricted
|
- Enzalutamide Capsules (Xtandi®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drug Fund: Enzalutamide
NICE TA316: Enzalutamide for metastatic hormone-relapsed prostate cancer, previously treated with docetaxel-containing regimen (July 2014)
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (January 2016)
TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer (May 2019)
|
Leuprorelin Acetate
|
Restricted
|
Leuprorelin Injection
|
|
|
| 08.03.04.03 |
Somatostatin analogues |
|
|
Lanreotide
|
Restricted
|
|
|
|
Octreotide
|
Restricted
|
Octreotide Injection
1. Symptoms associated with carcinoid tumours with features of carcinoid syndrome.
2. Prevention of complications following pancreatic surgery.
|
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Green - Drugs suitable for generalised use in accordance with position summary.
Inform primary care of need to prescribe using a TTO chart if in patient or Treatment Advice Note (TAN) if Outpatient.
|
|
Amber - these drugs require specialist initiation or recommendation |
|
Amber Share Care - Drugs suitable for generalist use, in accordance with position summary, normally following specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red. |
|
Red - Drugs for specialist use only, in accordance with position summary. GPs should not be asked to prescribe these products. |
|
Red ULM - Unlicensed medicines for specialist use only, in accordance with position summary. GPs should not be asked to prescribe these products. |
|
Grey drugs - No formal commissioning position. Check appropriate CCG /NHSE commissioning list or contact CCG/NHSE Medicines Management team for advice. Fill in individual funding request for appropriate CCG/NHSE. This will need to be signed by the Chief Pharmacist and a copy of the relevant DTC submission attached. |
|
Black - Drugs not routinely commissioned so should not usually be prescribed |
|
|
|
